ArticlePharmacoepidemiology and drug safety2026
Trends and Patterns of Adverse Drug Reaction Reporting in Sierra Leone: A Retrospective Analysis of VigiFlow Data (2008-2022).
Article in Pharmacoepidemiology and drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Elucidating adverse drug reactions and underlying molecular mechanisms of ivermectin through pharmacovigilance and multi-omics analysis.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAdverse drug reactions (ADRs) present significant obstacles for healthcare systems, impacting both patient safety and the effectiveness of treatments. Despite this, there is a scarcity of research on ADR reports in Sierra Leone, especially over long periods. This study aims to investigate the characteristics and reporting patterns found in the Sierra Leone pharmacovigilance database managed through VigiFlow.
methodThis study analyzes reports of ADRs from Sierra Leone's national pharmacovigilance database, VigiFlow, spanning from January 2008 to December 2022. Data collected included patient demographics (age, sex), reporter characteristics (type of reporter, year of reporting), and ADR-specific information (suspected medication, indication, ADR types (MedDRA), seriousness, outcome, actions taken, and time to onset), and completeness score. Descriptive statistics, chi-square tests, and the Kruskal-Wallis test with Bonferroni-adjusted post hoc tests were applied to identify patterns and associations within the dataset.
resultsA total of 3381 individual case safety reports (ICSRs) were analysed. The majority of reports involved females (54.7%) and adults aged 18 to 44 years (51.4%). Reporting rates increased after 2015, peaking in 2021. The most frequently implicated medications were anti-infective drugs (40.7%) and antiparasitic medicines (34.1%), particularly ivermectin, albendazole, and vaccines for cholera and yellow fever. The most commonly reported ADRs were headache (13.2%), fever (12.2%), and diarrhoea (7.6%), primarily affecting the nervous system and general disorder classes. Pharmacists were responsible for 39.0% of reports and achieved the highest completeness score, with a mean of 0.78. Age was significantly associated with the seriousness, outcome, and onset time of ADRs (p < 0.001), while gender was significantly associated with onset time (p = 0.007).
conclusionADR reporting in Sierra Leone has improved, with antiparasitic medicines and vaccines most frequently linked to reactions. Sustaining progress requires enhanced training, public engagement, and strengthened active pharmacovigilance to ensure completeness and patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.